Advertisement


Mairéad G. McNamara, PhD, MBBCh, on Neuroendocrine Carcinoma: Findings on Liposomal Irinotecan Plus Fluorouracil and Folinic Acid or Docetaxel

2022 ASCO Annual Meeting

Advertisement

Mairéad G. McNamara, PhD, MBBCh, of The Christie NHS Foundation Trust, discusses phase II findings of the NET-02 trial, which explored an unmet need in the second-line treatment of patients with progressive, poorly differentiated extrapulmonary neuroendocrine carcinoma. In the trial, the combination of liposomal irinotecan, fluorouracil, and folinic acid, but not docetaxel, met the primary endpoint of 6-month progression-free survival rate (Abstract 4005).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
The prognosis for patients with poorly differentiated neuroendocrine carcinoma, which is extrapulmonary is poor. Most of these patients present with advanced disease and their prognosis is usually less than a year. The treatment for these patients is predominantly like small cell lung cancer or lung neuroendocrine carcinoma. With these patients with extra pulmonary neuroendocrine carcinoma, they have an aggressive histology with a KI67, by definition being greater than 20%. The treatment in the first line advanced setting has been a platinum based treatment for the last 30 years and there's no standard treatment for a second line, and this is an area of unmet need. And therefore the NET-02 trial addresses this unmet need. In the NET-O2 trial, one of the treatment arms is liposomal irinotecan 5-fluorouracil folinic acid. This has been found and has been reported to increase intratumoral levels of irinotecan and SN-38, which is the active metabolite of irinotecan. The second arm in NET-02 trial is docetaxel, which has been used as a standard of care option in small cell lung carcinoma as per the NCCN guidelines. The key eligibility for this study was that patients should have extrapulmonary neuroendocrine carcinoma grade 3. With a KI67 of greater than 20% have received previous platinum based treatment and have an equal performance status of less than or equal to two. The primary endpoint for this study was six month PFS rate, with secondary endpoints being response rate, PFS, overall survival, toxicity, quality of life and translational endpoints. The quality of life and translational endpoint results will be presented at a later date. So patients had scans every eight weeks and continued on treatment until progressive disease or intolerable toxicity. The statistical design was allowing for a 5% dropout rate. There was an 80% power to detect the one-sided 95% confidence interval for the six month PFS rate and excluding 15% with the true rate being greater than 30%. So if a patient had a six month PFS rate of 30% or greater, that was the required level of efficacy, and a rate of 15% or less give grounds for rejection. These rates were based on review of retrospective data where the six month PFS rate was reported and ranged from 15% to 25%. So at a median follow up of 8.1 months, the six month PFS rate was, primary endpoint was met by liposomal irinotecan 5-fluorouracil with the six month PFS rate of being 31% with a 95% lower confidence limit of 17.25% and exceeding the rate of 15%, which was gave grounds for rejection. For docetaxel, the six month PFS rate was 13.8%, with a lower confidence limit of 4.85%. The median PFS for liposomal irinotecan was three months versus two for docetaxel. Median overall survival was nine months versus five for docetaxel. And the response rate was similar in both arms 10.3%. So in conclusion, the primary end point of six month PFS rate was met by liposomal irinotecan 5-fluorouracil folinic acid, but not docetaxel, exceeding the required threshold for efficacy. And the response rate was similar in both arms. The median overall survival was greater in the liposomal irinotecan arm, with the median overall survival of nine months versus five months with the docetaxel. The adverse events, the toxicity was similar with no new safety signals and based on these results, liposomal irinotecan warrants further exploration in these patients with extrapulmonary, poorly differentiated neuroendocrine carcinoma. And it would be important that guidelines would be developed using trial based evidence for these patients.

Related Videos

Breast Cancer

Robert Hugh Jones, MD, PhD, on Breast Cancer: Updated Overall Survival Data on Fulvestrant Plus Capivasertib

Robert Hugh Jones, MD, PhD, of Cardiff University and Velindre Hospital, discusses results from an updated analysis of the FAKTION trial, which showed improved overall survival with fulvestrant plus capivasertib in women with metastatic estrogen receptor–positive breast cancer whose disease had relapsed or progressed on an aromatase inhibitor. The benefit may be predominantly in patients with PIK3CA/AKT1/PTEN pathway–altered tumors, a topic researchers continue to study in the phase III CAPItello-291 trial (Abstract 1005).

 

Breast Cancer

Nancy Davidson, MD: In It for the Long Haul: Outcomes in Hormone Receptor–Positive Breast Cancer

Nancy Davidson, MD, of the Fred Hutchinson Cancer Research Center, reviews results from four abstracts about the importance of long-term follow-up in studies of adjuvant endocrine therapy for hormone receptor–positive breast cancer. Because the natural history of hormone receptor–positive breast cancer is long, an effort is underway to improve selection of patients by clinical parameters or biomarkers, refine the endocrine therapy background, and administer more effective combinations of endocrine therapy with other agents.

Bladder Cancer

Shilpa Gupta, MD, on Urothelial Cancer: Defining Who Is 'Platinum-Ineligible'

Shilpa Gupta, MD, of the Cleveland Clinic Foundation, discusses an updated consensus definition for standard therapy and clinical trial eligibility for patients with metastatic urothelial cancer who are platinum-ineligible, criteria that are proposed to guide treatment recommendations for this population. This may be especially important now that the U.S. Food and Drug Administration has restricted the use of first-line pembrolizumab to those who are considered platinum-ineligible (Abstract 4577).

Multiple Myeloma

Paul G. Richardson, MD, on Multiple Myeloma: New Data on Lenalidomide, Bortezomib, and Dexamethasone, With or Without ASCT

Paul G. Richardson, MD, of Dana-Farber Cancer Institute, discusses phase III findings from the DETERMINATION trial, which showed that, for patients with newly diagnosed multiple myeloma, lenalidomide, bortezomib, and dexamethasone (RVd) with or without autologous stem cell transplant (ASCT) and lenalidomide maintenance to disease progression resulted in the longest median progression-free survival reported for each approach, and a highly significant difference in progression-free survival in favor of early transplant. While overall response rates were similar, rates of MRD favored early transplant also, but toxicity was greater and quality of life was transiently but significantly diminished. No overall survival advantage has been observed to date (Abstract LBA4).

Michael J. Overman, MD, and Takayuki Yoshino, PhD, MD, on Colorectal Cancer: Phase III Data on Panitumumab or Bevacizumab Plus mFOLFOX6

Michael J. Overman, MD, of The University of Texas MD Anderson Cancer Center, and Takayuki Yoshino, PhD, MD, of the National Cancer Center Hospital East, Japan, discuss results from the PARADIGM trial, the first prospective study to test the superiority of panitumumab vs bevacizumab in combination with standard doublet first-line chemotherapy for patients with RAS wild-type and left-sided metastatic colorectal cancer. The study showed that panitumumab improved overall survival in combination with mFOLFOX6, which may establish a standard first-line combination regimen for this population (Abstract LBA1).

Advertisement

Advertisement



Advertisement